BiotechTube

Generic HAART Triomune : d4T, 3TC, NVP + Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

HIV

Conditions

HIV, AIDS, Kaposi's Sarcoma, Human Herpesvirus 8

Trial Timeline

Jan 1, 2003 → Mar 1, 2009

NCT ID
NCT00380770

About Generic HAART Triomune : d4T, 3TC, NVP + Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV

Generic HAART Triomune : d4T, 3TC, NVP + Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV is a approved stage product being developed by Cipla for HIV. The current trial status is completed. This product is registered under clinical trial identifier NCT00380770. Target conditions include HIV, AIDS, Kaposi's Sarcoma.

What happened to similar drugs?

20 of 20 similar drugs in HIV were approved

Approved (20) Terminated (1) Active (0)
✅Darunavir + Etravirine + Emtricitabine/tenofovir disoproxil fumarate + Raltegravir + Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs) + Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & availableAbbVieApproved
✅Lopinavir/RitonavirAbbVieApproved
✅Ritonavir boosted Atazanavir + Raltegravir + TDF/FTC (or 3TC)MerckApproved
✅RaltegravirMerckApproved
✅raltegravirMerckApproved
✅Kaletra + Isentress + Pre-study antiretroviral regimenMerckApproved
✅DOR/3TC/TDFMerckApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00380770ApprovedCompleted

Competing Products

20 competing products in HIV

See all competitors
ProductCompanyStageHype Score
DOR/ISLMerckPhase 2
35
Dolutegravir 50 mg twice daily + Dolutegravir placebo twice dailyShionogiPhase 3
40
GSK1265744 10 mg oral solution + GSK1265744 5 mg tablet + GSK1265744 5 mg tabletShionogiPhase 1
29
GW810781ShionogiPhase 2
35
Antiretroviral Therapy (ART) + Baricitinib (LY3009104) 2 mgEli LillyPhase 2
42
Epoetin alfaJohnson & JohnsonPre-clinical
26
LevofloxacinJohnson & JohnsonPhase 1
29
SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo + SHR2150；PlaceboJiangsu Hengrui MedicinePhase 1
29
ABBV-181 + PlaceboAbbViePhase 1
29
ABBV-382 + ABBV-382 + Placebo for ABBV-382AbbViePhase 1
29
Darunavir + Etravirine + Emtricitabine/tenofovir disoproxil fumarate + Raltegravir + Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs) + Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & availableAbbVieApproved
43
lopinavir/ritonavir + lamivudineAbbViePre-clinical
26
Lopinavir/RitonavirAbbVieApproved
43
Budigalimab + Placebo + Budigalimab + PlaceboAbbViePhase 1
29
Budigalimab + Placebo for Budigalimab + ABBV-382 + Placebo for ABBV-382 + BudigalimabAbbViePhase 2
27
CVC 150 mg + CVC 300 mgAbbViePhase 2
35
Rosuvastatin 10 mg. daily for 96 weeks + PlaceboAstraZenecaPhase 2
35
Raltegravir + Placebo + Current ARTMerckPhase 3
40
Indinavir sulfate + Lamivudine + ZidovudineMerckPhase 3
40
RosuvastatinAstraZenecaPhase 2
35